A synthesis of cell models, not clinical trials
The intracellular accumulation of misfolded alpha-synuclein is a hallmark of several diseases, including Parkinson’s, dementia with Lewy bodies and multiple system atrophy. However, the link between this accumulation and the progressive degeneration of nerve cells remains incompletely understood.
The authors searched three bibliographic databases for peer-reviewed studies published up to March 2026. The 33 included studies examined different forms of alpha-synuclein, including oligomers and preformed fibrils, in mammalian cell systems.
The models included neurons, glial cells and cells derived from induced pluripotent stem cells. This diversity allows comparisons across several biological contexts, but also makes comparisons between experiments more difficult.
Disruptions to energy production and cellular maintenance
According to the abstract, oligomeric and fibrillar forms of alpha-synuclein consistently caused a decrease in mitochondrial membrane potential, impaired oxidative phosphorylation and reduced ATP production. These findings concern cellular energy function, not measurements of fatigue or physical capacity in patients.
The researchers also report increased reactive oxygen species, mitochondrial fragmentation and defects in mitophagy, the process that removes damaged mitochondria. Several aspects of mitochondrial function therefore appear to be affected, beyond energy production alone.
These changes frequently preceded cell death. They were more pronounced in certain dopaminergic or genetically vulnerable models. This sequence supports a mechanistic hypothesis, without establishing that this damage alone explains disease progression in humans.
A research avenue, not therapeutic validation
The value of this synthesis lies in highlighting a mechanism shared across several experimental models. It does not establish that any drug, supplement or practice claimed to support mitochondria prevents or treats Parkinson’s.
The authors highlight methodological heterogeneity and call in particular for standardized fibril preparation, as well as multicellular human models and organoids. The gap between isolated cells and a disease progressing within an organism remains a central limitation.
Limitations to keep in mind
Only the PubMed abstract was consulted, not the full text. Detailed methods, effect sizes, comparators and exposure durations therefore cannot be examined here. The models are exclusively in vitro and show methodological heterogeneity. Funding and conflicts of interest have not been checked.
What we can take away
Mitochondrial damage offers a coherent mechanistic avenue for understanding alpha-synuclein toxicity. This review of cell studies does not validate any intervention in patients.
Sources and provenance
- Mitochondrial Dysfunction as a Convergent Mechanism of α-Synuclein Toxicity: A Systematic Review of In Vitro Fibrillar Models.
Source date: 2026-10-28.
Journal Article, Systematic Review, Review · Résumé PubMed uniquement, texte intégral non consulté